Background
==========

In the past few decades, antimicrobial resistance has been seen globally in several pathogenic microorganisms, including some that were antibiotic-sensitive until recently. This is probably due to the indiscriminate and irrational use of these medicines \[[@B1],[@B2]\]. According to the World Health Organization \[[@B1]\], the increase in antimicrobial resistance stems from a number of factors, including lack of knowledge about it among prescribing doctors, which leads to unnecessary prescriptions. Inadequate diagnosis or lack of diagnosis also leads to the use of antimicrobials against a \"possible infection\". Also, prescriptions for incorrect medicines or incorrect determinations of dose, route and/or duration of treatment often occur in response to pressure from companies or patients and the desire for profit. It has been recognized that medical visitors or commercially oriented publications are the main sources of information about medicines.

Another important consideration is the uncertainty of patients receiving antibiotics about whether the quality of a generic medicine is equal to, greater than or less than its equivalent brand-name drug. The belief that \"the more expensive the product, the more effective\" is shared by some doctors and pharmacists. This misconception leads to unnecessary use of the newest antibiotics simply because they are more expensive and broad-spectrum, and this in turn promotes the selection of microorganisms resistant to them, increasing expense without real benefit \[[@B1]\]. Within this myth of \"the more expensive, the more effective\" we can include innovative products and generic ones because the public tends to believe that the generic product, because of its low price, is of bad quality, and therefore ineffective. For all medicines (generic or brand-name), especially antibiotics, effectiveness and safety are vital qualities; without them, the health of the patient is at risk. To remove any doubts about antibiotics, we must evaluate their behaviors *in vitro*and *in vivo*in order to confirm their suitability for therapeutic use.

In order to dispel doubts about the efficacy of generic antibiotics, arising from complaints from the medical community and reported in the literature and at international meetings \[[@B3]-[@B5]\], our group decided to conduct a broad-based study focusing on the quality and effectiveness of commercial antibiotics in our country (Colombia). We have already studied the effectiveness of some compounds using biological assays with microorganisms: Ceftriaxone, Cefotaxime, Ceftazidime, Ampicillin/Sulbactam and Imipenem/Cilastatin. The results have shown that experimental, brand-name and generic products are pharmaceutical equivalents; they all fulfill the requirements of the U. S. Pharmacopoeia (XXVIII) in relation to their activities \[[@B6]\].

In this paper, we present a comparative study of Meropenem and Piperacillin/Tazobactam using commercial products (experimental, brand-name and generic). We evaluated their antimicrobial activities by determining their potencies, critical concentrations, minimal inhibitory concentrations and minimal lethal concentrations. In respect of these parameters, all the products meet the proper standards of quality for pharmaceutical products, so we conclude that they all exhibit the same level of antimicrobial activity.

Methods
=======

Microorganisms
--------------

To validate the microbiological assay for evaluating the potencies of Meropenem and Piperacillin, we used *Bacillus subtilis*ATCC 6633, *Staphylococcus aureus*ATCC 29737 and ATCC 6538p, *Pseudomonas aeruginosa*ATCC 25619 and ATCC 9027, *Micrococcus luteus*ATCC 9341, *Escherichia coli*ATCC 10536, *Klebsiella pneumoniae*ATCC 10031 and *Streptococcus faecalis*. For MIC and MLC studies we used *Acinetobacter baumanii*strains 59, 139, 147 and 173, vancomycin-resistant *Enterococcus gallinarum*, *Streptococcus faecalis*ATCC 29212, a nosocomial strain 319623 and a vancomycin-sensitive strain, *Escherichia coli*strains 39, 50 and 69, *Klebsiella pneumoniae*strains 1, 43, 63, 65 and 207, *Pseudomonas aeruginosa*strains 42, 74, 151 and 157, and *Staphylococcus aureus*strains 287, 291 and ATCC 25923. All microorganisms were grown in Mueller Hinton (MH) broth (incubated at 35°C for 24 h). Each strain was then plated on MH agar to obtain isolated colonies, which were then used to make larger cultures in MH medium. The cultures were harvested with cryopreservation broth. A portion of each was kept in a cryovial at -70°C, while the other portion was used to prepare a suspension with 25% transmittance at 600 nm (25%T) to develop *in vitro*assays. These suspensions were kept in cryovials at -70°C.

Analytical Bioassay
-------------------

This was established and validated for Meropenem and Piperacillin/Tazobactam. First, the most appropriate microorganisms were selected, the proper concentration range was determined, and the linearity, precision, specificity and stability of the compound in question were assessed \[[@B6]\]. All samples were then evaluated with the analytical bioassay under the chosen conditions.

Minimal Inhibitory Concentration (MIC) and Minimal Lethal Concentration (MLC)
-----------------------------------------------------------------------------

Assays to assess these parameters were developed in two parts. (1) **Preparation of inocula:**the number of colony forming units (CFU) was determined for each suspension at 25%T in order to prepare inocula of 1-5 × 10^6^CFU/ml. (2) **MIC and MLC determination by micro-dilution:**samples were diluted to 2 mg/ml for evaluation. Using a multichannel pipette, 100 μl of antibiotic sample was placed in each well of a 96-well ELISA plate, with 200 μl in column 12. Next, 100 μl of the antibiotic solution (2 mg/ml) was placed in the first column and thoroughly mixed by pipetting. From these wells, 100 μl was added to the second column and mixed, and this procedure was repeated up to column 10, after which the 100-μl portion was discarded. Columns 11 and 12 were positive and negative controls, respectively. Each row (A to H) represented a different sample to be analyzed. Each inoculum (100 μl) was then pipetted into each microplate, which was incubated at 37°C for 24 h. Growth in the wells was assessed. The lowest dilution showing no growth, the first dilution with growth, and the two controls were plated on to MH agar. The **MIC**was defined as the lowest dilution that showed no growth on the ELISA plate but showed growth on MH agar; the **MLC**was defined as the lowest dilution that did not show growth on either the ELISA plate or MH agar \[[@B7]\].

Critical Concentration (CC)
---------------------------

The CC was determined similarly to the analytical bioassay. The inocula for **MIC**and **MLC**determination and serial two-fold dilutions of each sample from 500 to 0.244 μg/ml were used. The halo of inhibition was measured, and the crown length X was calculated (inhibition halo diameter minus reservoir diameter divided by 2). Log concentration vs. X^2^was plotted, and linear regression (*y = mx + b*) was applied. The y-intercept (*b*) is equivalent to the log of the CC \[[@B7]\].

Spontaneous mutants
-------------------

Spontaneous mutation was analyzed similarly to the analytical bioassay. Again, the inocula for **MIC**and **MLC**determination were applied. Specific microorganisms and dilutions were selected after determination of critical concentrations. On each plate, a dilution of the USP standard and samples of the same concentration were used.

Samples
-------

Commercial products purchased from the pharmacies of different hospitals in Bogotá, D. C. Colombia, were analyzed. They included innovator (MERONEM^®^, TAZOCIN^®^), trademark products and generic products of Meropenem and Piperacillin/Tazobactam. All the samples declared the contents were 1 g. They were all diluted in sterile water in 100 ml volumetric flasks. The solutions were divided into 5 ml fractions for storage at -70°C; they were diluted to 1 mg/ml to develop the analytical bioassays and to 2 mg/ml for MIC and MLC assays.

Results
=======

Analytical Bioassay
-------------------

### Microorganism Selection

The selection criteria were well-defined edges on inhibition haloes, halo diameters no greater than 30 to 35 mm, and no generation of spontaneous mutants under antibiotic treatment \[[@B8],[@B9]\]. Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"} show the responses of various microorganisms to Meropenem and Piperacillin/Tazobactam, respectively. On the basis of these results, *B. subtilis*ATCC 6633 was selected for further experiments because it fulfilled all the criteria when treated with Meropenem and Piperacillin/Tazobactam.

![**Bioassay of Meropenem (USP standard) against (A) *Bacillus subtilis*ATCC 6633, (B) *Escherichia coli*ATCC 10536, (C) *Klebsiella pneumoniae*ATCC 10031, (D) *Micrococcus luteus*ATCC 9341, (E) *Pseudomonas aeruginosa*ATCC 25619 and (F) *Staphylococcus aureus*ATCC 29737**.](1472-6904-10-3-1){#F1}

![**Bioassay of Piperacillin (USP standard)/Tazobactam against (A) *Bacillus subtilis*ATCC 6633, (B) *Klebsiella pneumoniae*ATCC 10031, (C) *Micrococcus luteus*ATCC 9341, (D) *Pseudomonas aeruginosa*ATCC 25619, (E) *Staphylococcus aureus*ATCC 29737 and (F) *Streptococcus faecalis***. Cited on page 6.](1472-6904-10-3-2){#F2}

### Determination of culture medium pH, incubation time and concentration range

The results for Meropenem showed that pH 8 is optimal because the inhibition haloes were well defined at that pH. In the case of Piperacillin/Tazobactam, the optimum pH was between 6.0 and 6.5. Therefore, the assay for Meropenem is best carried out in antibiotic medium number 11 and the assay for Piperacillin/Tazobactam in antibiotic medium number 1.

The assays for both antibiotics require between 8 and 10 h incubation. This is less than many common assays, which require between 18 and 24 h.

Ten concentrations were used (two-fold dilutions from 250 to 0.488 μg/ml for Meropenem and from 1000 to 1.9531 μg/ml for Piperacillin/Tazobactam). Table [1](#T1){ref-type="table"} shows that linearity was best in the range between C5 and C9 (15.62 to 0.9976 μg/ml) (R^2^= 0.9996). For practical reasons, however, the range was adjusted to 25 μg/ml to 1.5625 μg/ml, which also showed good linearity (R^2^= 0.9996, Figure [3](#F3){ref-type="fig"}).

###### 

Evaluation of the range of concentrations for Meropenem (USP standard)

  Concentration Range   Equation                                
  --------------------- ---------- ------------ --------------- ------------
  **From**              **To**     **Slope**    **Intercept**   **R^2^**
                                                                
  **C1**                C9         3.8469       15.355          0.995
  **C1**                C5         4.288        13.36           0.9861
  **C2**                C6         3.4631       16.437          0.9911
  **C3**                C7         3.5659       15.967          0.9881
  **C4**                C8         3.6377       15.735          0.9878
  **C5**                **C9**     **3.8575**   **15.374**      **0.9976**
  **C6**                C10        3.9901       15.42           0.9945

![**Calibration curve of ten concentrations of Meropenem to determine the optimal test range**.](1472-6904-10-3-3){#F3}

With Piperacillin/Tazobactam, our analysis demonstrated that the concentrations between C5 and C10 generated inhibition haloes of the appropriate diameter, so this range was evaluated (Figure [4](#F4){ref-type="fig"}). For concentrations between C1 and C4, the inhibition zones had diameters greater than 30 mm. Table [2](#T2){ref-type="table"} shows the range between C5 to C9 to be the most linear (R^2^= 0.9989).

###### 

Evaluation of the range of concentrations of Piperacillin (USP standard)/Tazobactam

  Concentration Range   Equation                                
  --------------------- ---------- ------------ --------------- ------------
  **From**              **To**     **Slope**    **Intercept**   **R^2^**
  **C5**                **C9**     **2.5554**   **9.8253**      **0.9989**
  C6                    C10        2.7968       9.1638          0.992

![**Calibration curve with 10 concentration levels of Piperacillin/Tazobactam to determine the optimal test range**.](1472-6904-10-3-4){#F4}

### Linearity

In Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, antibiotic concentration correlates well with the diameter of the zone of inhibition.

###### 

Evaluation of linearity for Meropenem and Piperacillin/Tazobactam

                                  Experimental t   Theoretical t   Decision   
  ----------------- ------------- ---------------- --------------- ---------- -------------
  **Slope**         H~0~: m = 0                    2.684           2.16       Reject H~0~
                    H~1~: m ≠ 0   7.677                                       
  **Intercept**     H~0~: b = 0                    18.025                     Reject H~0~
                    H~1~: b ≠ 0   47.901                           2.16       
  **Correlation**   H~0~: R = 0   58.41            23.381          2.16       Reject H~0~
                    H~1~: R ≠ 0                                               

###### 

Regression analysis by analysis of variance (ANOVA).

                                                  Experimental t                   
  ---------------- ------------------------------ ---------------- -------- ------ -------------
                   H~0~: There is no regression   3494.54          324.89   3.67   Reject H~0~
  **Regression**   H~1~: There is regression                                       
                   H~0~: There is no deviation                                     
  **Linearity**    from linearity                                                  
  **Deviation**    H~1~: There is a deviation     0.3513           3.71     3.71   Accept H~0~
                   from linearity                                                  

From this point on, the selected concentrations will be designated C1 to C5 for clarity.

### Precision

The reproducibility and between-days precision of our assays were evaluated in several ways. Reproducibility was studied by determining the coefficient of variation. This was less than 1%, which is acceptable for analytical assays in the pharmaceutical industry. The Cochran test was also applied, and the results showed that the variances at each concentration were equivalent. Finally, ANOVA for each concentration demonstrated no significant differences between two samples run on the same day (Table [5](#T5){ref-type="table"}).

###### 

ANOVA of the reproducibility of assays using Meropenem and Piperacillin/Tazobactam

  Concentration   Experimental F   Theoretical F   Decision   
  --------------- ---------------- --------------- ---------- -------------
  **C1**          2.9136           2.684           5.99       Accept H~0~
  **C2**          3.9852           3.025           5.99       Accept H~0~
  **C3**          1.1247           1.009           5.99       Accept H~0~
  **C4**          0.4746           0.395           5.99       Accept H~0~
  **C5**          0.4938           0.412           5.99       Accept H~0~

The between-days precision was also analyzed. ANOVA showed that for the antibiotics evaluated, the results of assays performed on different days did not differ significantly (Table [6](#T6){ref-type="table"}).

###### 

ANOVA of the between-days precision of assays using Meropenem and Piperacillin/Tazobactam

  Concentration   Experimental F   Theoretical F   Decision   
  --------------- ---------------- --------------- ---------- -------------
  **C1**          0.2747           0.6425          5.99       Accept H~0~
  **C2**          0.0169           0.2342          5.99       Accept H~0~
  **C3**          0.6447           0.4756          5.99       Accept H~0~
  **C4**          0.8572           0.9325          5.99       Accept H~0~
  **C5**          0.0712           0.123           5.99       Accept H~0~

### Stability

The stability of each compound during the experimental period was verified. Solutions of Meropenem and Piperacillin/Tazobactam (1 mg/ml; USP Standard) were incubated at 37°C, and samples were taken after 0, 6, 12, 24, and 48 h and six days of incubation. The corresponding dilutions were then evaluated, and the results were plotted and compared to reveal any reduction in antibiotic activity (i.e., a decrease in the diameter of the zone of inhibition).

From the equation *y = mx + b*, where *y*represents the inhibition zone diameter and *x*represents the log of the concentration, changes in the *b*value indicate changes in activity. If there is no change in the intercept, the antibiotic is stable. If the *b*value decreases, this indicates instability or a loss of activity.

In the case of Meropenem, the solution showed a slight decrease in the intercept value after 24 h incubation (Table [7](#T7){ref-type="table"}). From this result, it appears that the molecule remained stable during our assays.

###### 

Stability of Meropenem and Piperacillin/Tazobactam in water for injection at 37°C

  Time       Meropenem   Piperacillin/Tazobactam                              
  ---------- ----------- ------------------------- -------- -------- -------- --------
  0 hours    4.1977      16.556                    0.9922   2.7549   9.2827   0.9969
  6 hours    ND          ND                        ND       2.717    14.247   0.9946
  12 hours   ND          ND                        ND       2.7162   16.39    0.9986
  24 hours   4.4628      15.921                    0.9976   2.6777   9.4456   0.9896
  48 hours   4.1291      13.257                    0.9847   3.2429   7.1086   0.9806
  6 days     4.1659      5.671                     0.9998   2.5459   7.0209   0.9603

ND: Not determined

Piperacillin/Tazobactam showed more interesting results. After 6 and 12 h the solution was more active, indicated by an increase in the intercept value (Table [7](#T7){ref-type="table"}). In other assays under different conditions (incubation at 4°C or 25°C), the solutions showed the same trend (Table [8](#T8){ref-type="table"}). High-performance liquid chromatography (HPLC) or mass spectrometry would be necessary to identify any structural or conformational change in the compound that could explain this activity increase. Most intriguingly, the activity returned to its initial levels after 24 h.

###### 

Stability of Piperacillin/Tazobactam in water for injection at 4°C and 25°C

  Time       4°C      25°C                                
  ---------- -------- -------- -------- -------- -------- --------
  0 hours    2.8549   9.2827   0.9969   2.7549   9.2827   0.9969
  6 hours    2.8705   10.204   0.9949   2.7902   10.32    0.9892
  12 hours   2.8234   13.45    0.9895   2.7247   13.355   0.9838
  24 hours   2.8507   10.185   0.99     2.7927   9.4542   0.9908
  48 hours   2.8802   8.9856   0.9955   2.8346   9.4962   0.9929
  6 days     2.8158   9.4177   0.9987   2.8067   7.2892   0.9995

### Specificity

Solutions of the antibiotics were incubated at 50°C. The Meropenem solution lost its activity after 22 days, meaning that it was the only molecule in solution responsible for the antimicrobial activity. The activity of Piperacillin/Tazobactam was lost after six days.

Sample analysis
---------------

The samples were analyzed in two groups. The first was used when the assay was being validated, and the second to evaluate antimicrobial activity by determining the MIC, MLC and CC values for each antibiotic. The results were quantified using the statistical method described by Hewitt (1977). Table [9](#T9){ref-type="table"} shows the content of each antibiotic in the samples purchased, and in each case the values fulfill the criteria laid out by USP 29 NF 24 for intravenous Piperacillin and Meropenem: **\"\...Contents no less than 90% and no more than 120% of Piperacillin, calculated on anhydrous base of the quantity registered of Piperacillin\"**and **\"\...Contents no less than 90% and no more than 120% of Meropenem, calculated on anhydrous base of the quantity registered of Meropenem.\"**

###### 

Contents of the commercial samples

  Samples   Piperacillin/Tazobactam   Meropenem            
  --------- ------------------------- ----------- -------- -------
  1         103.9                     103.6       100.85   107.5
  2         99.0                      115.8       94.9     109.5
  3         116.0                     109.7       93.52    105.3
  4         110.8                     109.4       94.30    116.9
  5         119.2                     108.7       91.92    104.5
  6         1156                      105.3       97.75    105.9
  7         110.6                     110.5       94.02    107.2
  8         113.9                     111.3       94.64    115.7
  9         114.7                     104.2       90.76    107.2
  10        116.2                     107.9       92.89    103.3
  11        111.2                     116.8       93.32    105.7
  12        112.4                     117.6       95.28    107.1
  13        114.6                     114.3       95.29    102.5
  14        116.2                     108.9       92.86    103.4
  15        108.2                     110.1       93.43    106.2
  16        114.1                     108.5       93.84    104.5
  17        117.9                     112.6       94.22    105.1
  18        110.3                     104.9       97.32    106.7
  19        114.8                                          105.8
  20        111.9                                          107.1
  21        109.9                                          

Minimal inhibitory and lethal concentrations
--------------------------------------------

Using previously described methods, the samples were analyzed in groups of seven per plate, each plate being inoculated with a single microorganism. The first row of the plate corresponded to the USP standard; the other seven rows contained the samples. Figure [5](#F5){ref-type="fig"} shows the results for Piperacillin/Tazobactam. The plate shows the same performance for the standard as for the samples.

![**MIC and MLC assay for Piperacillin/Tazobactam**.](1472-6904-10-3-5){#F5}

That is, growth was inhibited at the same concentration of each sample. After replication on to MH agar, there was no growth in concentrations C1 to C5 or C12, but there was growth in C6 to C11. This means that the antibiotic has an MLC but no MIC. The MLC is C5 for the USP standard and for all the samples. For all samples, using all microorganisms evaluated, the results showed the same performances for both molecules (Tables [10](#T10){ref-type="table"} and [11](#T11){ref-type="table"} include results for only some samples, as illustration).

###### 

Determination of MIC and MLC for Meropenem

  ------------------------------ ----------------- ----------------- -------- --------- -------- --------
  **Strain**                     **MIC (μg/ml)**   **MLC (μg/ml)**                               
                                                                                                 
                                 **Std**           **M1**            **M2**   **Std**   **M1**   **M2**
                                                                                                 
  *Ps*. *aeruginosa*151          3.9               3.9               3.9      7.8       7.8      7.8
  *Ps*. *aeruginosa*157          15.6              15.6              15.6     31.3      31.3     31.3
  *Ps*. *aeruginosa*ATCC 25619   31.3              31.3              31.3     62.5      62.5     62.5
  *Ps*. *aeruginosa*74           31.3              31.3              31.3     62.5      62.5     62.5
  *Ps*. *aeruginosa*142          15.6              15.6              15.6     31.3      31.3     31.3
  *A*. *baumanii*59              62.5              62.5              62.5     125       125      125
  *A*. *baumanii*147             15.6              15.6              15.6     31.3      31.3     31.3
  *A*. *baumanii*173             0.98              0.98              0.98     1.95      1.95     1.95
  *A*. *baumanii*189             15.6              15.6              15.6     31.3      31.3     31.3
  *E. coli*39                    3.91              3.91              3.91     7.8       7.8      7.8
  *E. coli*50                    62.5              62.5              62.5     125       125      125
  *E. coli*69                    31.3              31.3              31.3     125       125      125
  *E. coli*ATCC 13706            ≥ 500             ≥ 500             ≥ 500    ≥ 500     ≥ 500    ≥ 500
  *S*. *faecalis*                ≥ 500             ≥ 500             ≥ 500    ≥ 500     ≥ 500    ≥ 500
  *S*. *faecalis*ATCC 29212      31.3              31.3              31.3     62.5      62.5     62.5
  *S*. *faecalis*ATCC 319623     31.3              31.3              31.3     62.5      62.5     62.5
  *E*. *gallinarum*              15.6              15.6              15.6     31.3      31.3     31.3
  *K. pneumoniae*1               62.5              62.5              62.5     125       125      125
  *K. pneumoniae*43              250               250               250      ≥ 500     ≥ 500    ≥ 500
  *K. pneumoniae*63              31.3              31.3              31.3     125       125      125
  *K. pneumoniae*65              15.6              15.6              15.6     31.3      31.3     31.3
  *K. pneumoniae*207             3.9               3.9               3.9      7.8       7.8      7.8
  *K. pneumoniae*ATCC10031       125               125               125      250       250      250
  ------------------------------ ----------------- ----------------- -------- --------- -------- --------

###### 

Determination of MIC and MLC for Piperacillin/Tazobactam

  Strain                           MIC (μg/ml)   MLC (μg/ml)                             
  -------------------------------- ------------- ------------- ------- -------- -------- --------
  *A*. *baumanii*(*A. b*.) 59      500           500           500     1000     1000     1000
  *A*. *baumanii*139               500           500           500     1000     1000     1000
  *A*. *baumanii*147               500           500           500     1000     1000     1000
  *A*. *baumanii*173               Nd            Nd            Nd      125      125      125
  *S*. *faecalis*(*S. f*.)         Nd            Nd            Nd      31.25    31.25    31.25
  *S*. *faecalis*ATCC 29212        Nd            Nd            Nd      250      250      250
  *S*. *faecalis*ATCC 319623       1000          1000          1000    \>1000   \>1000   \>1000
  *E. gallinarum*(*E. g*.)         3.95          3.95          3.95    7.81     7.81     7.81
  *E. coli*(*E. c*.) 39            Nd            Nd            Nd      7.81     7.81     7.81
  *E. coli*50                      1000          1000          1000                      
  *E. coli*69                      62.25         62.25         62.25   250      250      250
  *K. pneumoniae*(*K. p.)*1        Nd            Nd            Nd      62.51    62.51    62.51
  *K. pneumoniae*43                R             R             R       R        R        R
  *K. pneumoniae*63                Nd            Nd            Nd      1000     1000     1000
  *K. pneumoniae*65                Nd            Nd            Nd      500      500      500
  *K. pneumoniae*207               R             R             R       R        R        R
  *Ps*. *aeruginosa*(*P. a*.) 42   Nd            Nd            Nd      7.81     7.81     7.81
  *Ps*. *aeruginosa*74             125           125           125     250      250      250
  *Ps*. *aeruginosa*151            31.25         31.25         31.25   62.51    62.51    62.51
  *Ps*. *aeruginosa*157            62.51         62.51         62.51   125      125      125
  *St. aureus*(*S. a*.) *287*      Nd            Nd            Nd      7.81     7.81     7.81
  *St. aureus 291*                 31.25         31.25         31.25   62.51    62.51    62.51
  *St. aureus 25923*               Nd            Nd            Nd      31.25    31.25    31.25

Critical concentration (CC)
---------------------------

The CC is the minimal concentration that inhibits microorganism growth. It is reached at the limit of the inhibition halo. It is a measure of the microorganism\'s sensitivity and can be two to four times greater than the MIC, which is determined under different conditions. The CC can be defined mathematically as Ln(CC) = Ln(C~O~) - X^2^/DT~O~, where CC is the critical concentration, C~O~is the antibiotic concentration in the reservoir, X is the length of the crown (see above), D is the diffusion coefficient, and T~O~is the critical time. The intercept of a plot of Ln (C~O~) vs. X^2^is the Ln of CC \[[@B7]\].

Figure [6](#F6){ref-type="fig"} shows the different behaviors of the microorganisms tested with Meropenem and Piperacillin/Tazobactam standards. In Figures [6A](#F6){ref-type="fig"} and [6B](#F6){ref-type="fig"}, the inhibition haloes are very diffuse, whereas Figures [6C](#F6){ref-type="fig"} and [6D](#F6){ref-type="fig"} correspond to microorganisms with well-defined haloes. Some microorganisms exhibited growth of spontaneous mutants (e.g., Figure [6D](#F6){ref-type="fig"}), allowing a new means of comparing the performances of the products tested to be developed. A well-defined inhibition halo was the selection criterion for evaluating CC. For the Meropenem assay, *P. aeruginosa*151 and 157 and *A. baumanii*148 and *K. pneumoniae*were selected, and for Piperacillin/Tazobactam, the selected microorganisms were *E*. *faecalis*, *E*. *faecalis*ATCC 29212, *P*. *aeruginosa*42, 74 and 151 and *S. aureus*287. Figure [7](#F7){ref-type="fig"} shows the correlation of X^2^with the log of antibiotic concentration. The equation is *y*= 0.0203*x*+ 1.4183, and *b*is therefore 1.4183. The CC is equivalent to antilog (1.4183), i.e., 26.2 μg/ml.

![**Zones of growth inhibition produced by Meropenem against (A) *K. pneumoniae*ATCC 10031, (B) *K. pneumoniae*65, (C) *P. aeruginosa*151, and (D) *A. baumanii*147**.](1472-6904-10-3-6){#F6}

![**Determination of critical concentration of Piperacillin/Tazobactam against *E. gallinarum***.](1472-6904-10-3-7){#F7}

The CC values for the different Meropenem and Piperacillin/Tazobactam samples showed no significant differences, meaning that the products behaved in similar ways against the different microorganisms tested (Tables [12](#T12){ref-type="table"} and [13](#T13){ref-type="table"}). On this basis, the generic products manufactured to meet all the quality standards applied to pharmaceutical products perform as well as the newest versions of those products.

###### 

Critical concentrations for different samples of Meropenem against different microorganisms.

  Sample         Critical Concentration (μg/ml)                                   
  -------------- -------------------------------- ------- ------- ------- ------- -------
  **Standard**   3.253                            0.437   0.512   0.439   1.533   0.107
  **M1**         3.474                            0.467   0.547   0.469   1.637   0.114
  **M2**         3.461                            0.465   0.545   0.467   1.631   0.114
  **M3**         3.490                            0.469   0.549   0.471   1.645   0.115
  **M4**         3.660                            0.492   0.576   0.494   1.725   0.120
  **M5**         3.377                            0.454   0.531   0.456   1.591   0.111
  **M6**         3.403                            0.457   0.536   0.459   1.604   0.112
  **M7**         3.461                            0.465   0.545   0.467   1.631   0.114
  **M8**         3.692                            0.496   0.581   0.498   1.740   0.121
  **M9**         3.445                            0.463   0.542   0.465   1.623   0.113
  **M10**        3.390                            0.455   0.534   0.457   1.597   0.111
  **M11**        3.409                            0.458   0.537   0.460   1.607   0.112
  **M12**        3.445                            0.463   0.542   0.465   1.623   0.113
  **M13**        3.377                            0.454   0.531   0.456   1.591   0.111
  **M14**        3.338                            0.448   0.525   0.450   1.573   0.110
  **M15**        3.425                            0.460   0.539   0.462   1.614   0.113
  **M16**        3.373                            0.453   0.531   0.455   1.590   0.111
  **M17**        3.380                            0.454   0.532   0.456   1.593   0.111
  **M18**        3.419                            0.459   0.538   0.461   1.611   0.112
  **M19**        3.455                            0.464   0.544   0.466   1.628   0.114
  **M20**        3.435                            0.461   0.541   0.464   1.619   0.113

###### 

Critical concentrations of different samples of Piperacillin/Tazobactam against various microorganisms.

  Sample     Critical Concentration (μg/ml)                                                
  ---------- -------------------------------- -------- -------- -------- -------- -------- --------
  Standard   16.069                           29.648   26.182   23.714   24.210   17.458   35.400
  M1         16.696                           30.775   27.386   24.662   25.348   18.296   36.887
  M2         18.399                           33.918   29.847   27.200   27.745   19.955   40.604
  M3         17.500                           32.198   28.303   25.611   26.268   18.977   38.586
  M4         17.451                           32.228   28.512   25.658   26.244   18.977   38.444
  M5         17.403                           32.020   28.355   25.706   26.147   18.907   38.374
  M6         16.809                           31.042   27.439   24.876   25.324   18.296   37.170
  M7         17.516                           32.554   28.695   26.061   26.583   19.117   38.869
  M8         18.014                           33.325   29.559   26.749   27.261   19.588   39.648
  M9         16.905                           31.160   27.465   25.018   25.614   18.401   37.099
  M10        17.098                           31.694   27.936   25.255   25.760   18.663   37.949
  M11        18.576                           34.214   30.319   27.318   28.036   20.252   41.029
  M12        19.107                           35.311   31.340   28.290   28.810   20.793   42.197
  M13        18.174                           33.503   29.769   26.820   27.358   19.867   40.214
  M14        17.500                           32.376   28.721   25.777   26.244   19.047   38.728
  M15        17.757                           32.880   28.983   26.275   26.752   19.344   39.082
  M16        17.355                           31.991   28.303   25.540   26.026   18.855   38.232
  M17        17.982                           32.939   29.245   26.512   26.922   19.501   39.613
  M18        16.937                           31.427   27.727   24.947   25.639   18.418   37.276

In addition, the ratio between sample CC and standard CC is similar to the ratio of antibiotic contents. In others words, all samples perform the same with regard to their antimicrobial activities *in vitro*(Tables [14](#T14){ref-type="table"} and [15](#T15){ref-type="table"}).

###### 

Ratio of sample CC/standard CC for Meropenem

  Sample   Sample CC/standard CC ratio   Ratio Median   Content                                   
  -------- ----------------------------- -------------- --------- ------- ------- ------- ------- -------
  M1       106.8                         106.9          106.8     106.8   106.8   106.5   106.8   107.5
  M2       106.4                         106.4          106.4     106.4   106.4   106.5   106.4   109.5
  M3       107.3                         107.3          107.2     107.3   107.3   107.5   112.5   105.3
  M4       112.5                         112.6          112.5     112.5   112.5   112.1   103.8   116.9
  M5       103.8                         103.9          103.7     103.9   103.8   103.7   104.6   104.5
  M6       104.6                         104.6          104.7     104.6   104.6   104.7   106.4   105.9
  M7       106.4                         106.4          106.4     106.4   106.4   106.5   113.4   107.2
  M8       113.5                         113.5          113.5     113.4   113.5   113.1   105.9   115.7
  M9       105.9                         105.9          105.9     105.9   105.9   105.6   104.1   107.2
  M10      104.2                         104.1          104.3     104.1   104.2   103.7   104.8   103.3
  M11      104.8                         104.8          104.9     104.8   104.8   104.7   105.9   105.7
  M12      105.9                         105.9          105.9     105.9   105.9   105.6   103.8   107.1
  M13      103.8                         103.9          103.7     103.9   103.8   103.7   102.6   102.5
  M14      102.6                         102.5          102.5     102.5   102.6   102.8   105.3   103.4
  M15      105.3                         105.3          105.3     105.2   105.3   105.6   103.7   106.2
  M16      103.7                         103.7          103.7     103.6   103.7   103.7   103.9   104.5
  M17      103.9                         103.9          103.9     103.9   103.9   103.7   105.0   105.1
  M18      105.1                         105.0          105.1     105.0   105.1   104.7   106.3   106.7
  M19      106.2                         106.2          106.3     106.2   106.2   106.5   105.6   105.8
  M20      105.6                         105.5          105.7     105.7   105.6   105.6   103.8   107.1

###### 

Ratio of sample CC/standard CC for Piperacillin/Tazobactam

  Sample   Sample CC/standard CC ratio   Ratio Median   Content                                           
  -------- ----------------------------- -------------- --------- ------- ------- ------- ------- ------- -------
  M1       103.9                         103.8          104.6     104.0   104.7   104.8   104.2   104.3   103.6
  M2       114.5                         114.4          114.0     114.7   114.6   114.3   114.7   114.5   115.8
  M3       108.9                         108.6          108.1     108.0   108.5   108.7   109.0   108.5   109.7
  M4       108.6                         108.7          108.9     108.2   108.4   108.7   108.6   108.6   109.4
  M5       108.3                         108.0          108.3     108.4   108.0   108.3   108.4   108.3   108.7
  M6       104.6                         104.7          104.8     104.9   104.6   104.8   105.0   104.8   105.3
  M7       109.0                         109.8          109.6     109.9   109.8   109.5   109.8   109.6   110.5
  M8       112.1                         112.4          112.9     112.8   112.6   112.2   112.0   112.4   111.3
  M9       105.2                         105.1          104.9     105.5   105.8   105.4   104.8   105.3   104.2
  M10      106.4                         106.9          106.7     106.5   106.4   106.9   107.2   106.7   107.9
  M11      115.6                         115.4          115.8     115.2   115.8   116.0   115.9   115.7   116.8
  M12      118.9                         119.1          119.7     119.3   119.0   119.1   119.2   119.2   117.6
  M13      113.1                         113.0          113.7     113.1   113.0   113.8   113.6   113.3   114.3
  M14      108.9                         109.2          109.7     108.7   108.4   109.1   109.4   109.1   110.1
  M15      110.5                         110.9          110.7     110.8   110.5   110.8   110.4   110.7   110.1
  M16      108.0                         107.9          108.1     107.7   107.5   108.0   108.0   107.9   108.5
  M17      111.9                         111.1          111.7     111.8   111.2   111.7   111.9   111.6   112.6
  M18      105.4                         106.0          105.9     105.2   105.9   105.5   105.3   105.6   104.9

Spontaneous mutants
-------------------

It was noted in the previous assays that some strains produced spontaneous mutants (Figure [6](#F6){ref-type="fig"}), indicated by the appearance of colonies within the inhibition halo. Therefore, an assay to assess spontaneous mutation was developed with appropriate concentrations of antibiotics. Each experimental set-up included an agar plate inoculated with the test strain. Of the six reservoirs, two contained standard solutions and the other four contained sample solutions, as shown in Figure [8](#F8){ref-type="fig"}. The numbers of mutants produced by the standard and sample solutions were counted after incubation.

![**Diffusion gel assay testing the production of spontaneous Meropenem-resistant mutants, with *A. baumanii*147 as a control strain and *K. pneumoniae*63 as a mutant-producing strain**.](1472-6904-10-3-8){#F8}

For Meropenem, the strains selected were *A. baumanii*147 as a control strain (showing no production of spontaneous mutants), *A. baumanii*189, *E. coli*39 and 69, and *K. pneumoniae*43 and 63. For Piperacillin/Tazobactam, the strains selected were *P. aeruginosa*151 as a control strain (showing no production of spontaneous mutants), *P. aeruginosa*74 and *A. baumanii*189. After statistical analysis, the results (Tables [16](#T16){ref-type="table"} and [17](#T17){ref-type="table"}) showed no significant differences in the production of spontaneous mutants for any of the strains tested.

###### 

Spontaneous mutant production in the diffusion gel assay for Meropenem

  Sample     *A. b*. 189   *E. c*. 39   *E. c*. 69   *K. p*. 43   *K. p*. 63                                      
  ---------- ------------- ------------ ------------ ------------ ------------ ------- -------- ------- --------- -------
  Standard   25.333        1.366        205.333      5.354        43.333       2.582   43.333   2.582   203.167   2.137
  M1         29.333        1.528        209.667      2.082        40.333       1.528   40.333   1.528   182.667   2.517
  M2         22.667        1.528        207.333      1.528        46.333       3.055   46.333   3.055   198.667   4.041
  M3         26.667        2.082        210.333      1.527        43.667       1.155   43.667   1.155   213.667   4.163
  M4         22.000        2.000        208.000      2.000        44.667       1.528   44.667   1.528   200.000   6.245
  M5         29.000        1.000        205.000      2.000        46.667       1.528   46.667   1.528   213.000   6.000
  M6         29.333        2.082        209.667      1.155        41.333       1.528   41.333   1.528   196.667   7.095
  M7         27.000        3.000        207.667      1.155        44.000       2.000   44.000   2.000   213.333   8.021
  M8         23.000        2.000        207.667      1.155        45.667       1.528   45.667   1.528   202.333   6.110
  M9         23.000        2.000        204.667      1.528        46.000       2.000   46.000   2.000   198.667   6.807
  M10        29.000        2.000        202.333      2.517        47.667       1.528   47.667   1.528   213.667   8.083
  M11        24.667        1.528        203.000      3.000        44.333       1.155   44.333   1.155   203.333   8.737
  M12        26.667        1.528        210.000      1.000        40.000       1.000   40.000   1.000   188.333   4.163
  M13        29.000        1.000        209.333      2.517        40.333       1.528   40.333   1.528   198.667   5.686
  M14        24.667        1.155        202.667      3.786        44.333       1.528   44.333   1.528   203.667   6.110
  M15        21.333        1.528        205.000      1.000        41.000       1.000   41.000   1.000   215.333   6.028
  M16        28.333        1.155        208.667      1.528        44.667       1.528   44.667   1.528   199.000   4.000
  M17        29.333        2.333        212.000      3.000        43.333       1.155   43.333   1.155   201.333   3.512
  M18        23.667        1.155        205.000      1.000        46.000       1.000   46.000   1.000   209.000   9.165
  M19        21.333        1.155        203.000      3.000        40.000       1.000   40.000   1.000   218.333   3.055
  M20        23.333        2.516        204.667      2.082        45.667       1.155   45.667   1.155   210.333   7.095
                                                                                                                  
  F          8.715         3.571        6.076        4.683        7.294                                           
  Prob.      0.000         0.000        0.000        0.000        0.000                                           
  V C F      1.808         1.808        1.808        1.808        1.808                                           

###### 

Spontaneous mutant production in the diffusion gel assay for Piperacillin/Tazobactam

  Sample     *A. b*. 189   *P. a*. 54            
  ---------- ------------- ------------ -------- -------
  Standard   125.17        1.472        110.00   9.381
  M1         127.00        1.000        109.33   1.528
  M9         123.67        2.517        104.67   1.528
  M18        124.33        1.528        105.00   1.000
  M6         125.67        1.528        109.67   1.155
  M10        127.67        3.055        102.33   2.517
  M16        128.33        1.528        109.67   0.577
  M5         128.00        1.000        105.00   2.000
  M14        124.33        1.155        101.67   2.082
  M4         122.67        0.577        108.00   2.000
  M3         125.67        2.082        111.00   1.732
  M15        123.33        2.082        105.00   1.000
  M7         127.67        1.528        107.67   1.155
  M8         123.00        1.732        107.67   1.155
  M17        129.33        5.859        108.67   1.528
  M13        126.67        1.155        107.00   2.000
  M2         123.33        1.528        107.33   1.528
  M11        125.33        1.528        103.00   3.000
  M12        125.67        2.517        110.00   1.000
                                                 
  F          2.657         1.898                 
  prob.      0.005         0.045                 

Discussion
==========

The activity of an antibiotic can be assessed under controlled conditions by comparing the inhibition of growth of sensitive microorganisms by known concentrations of that antibiotic with a reference standard, producing meaningful results by well characterized methods \[[@B9]-[@B11]\]. The experiment to evaluate assay performance showed that it fulfilled the requirements (linearity, repeatability, precision). In the case of Meropenem, the best linearity was shown over the range 25 μg/ml to 1.5625 μg/ml, where the correlation was highest (R^2^= 0.9996). For Piperacillin/Tazobactam, the range from 62.5 μg/ml to 3.906 μg/ml was the most linear, with an R^2^value of 0.9989. The reproducibility and between-days precision of both assays had coefficients of variation less than 1%, and ANOVA showed no significant differences at any concentration. Antibiotic activity remained stable over the course of the assay at the selected temperature. Finally, the inhibition assay results were due only to the molecules evaluated. In conclusion, the assay was exact and accurate, with reproducible results.

Our results with Meropenem were generally similar to those of Mendez et al. (2005), but with some differences. Our work used *B. subtilis*ATCC 6633 as a test strain, while they selected *M. luteus*ATCC 9341. We used ten concentrations to ensure better statistical analysis; the other study only used three. However, Mendez et al. confirmed their results using HPLC. Similar results were reported by Zuluaga et al. (2009), who evaluated other antibiotics (Amikacin, Gentamicin and Vancomicyn). We conclude that antibiotics can be evaluated by established bioassays using an appropriate test microorganism and conditions, even though some evidence indicates high variability in bioassays.

Analysis of commercial versions of the antibiotics tested (innovator, trade mark and generic products) indicated that all the samples can be considered pharmaceutical equivalents because they fulfill the standards of the USP Pharmacopoeia (Table [9](#T9){ref-type="table"}). Zuluaga et al. (2009) proposed a comparison of performances of all samples by linear correlation against the performances of an innovator to determine pharmaceutical equivalence. First, the content is determined in a comparison against USP standard (the so-called gold standard). In that study, the performance of all samples was similar to the standard, and the results were accurate and reproducible. Therefore, it is redundant to compare the behaviors of novel drugs against other samples. It is sufficient to determine whether they fulfill the standards of the appropriate regulatory agency because this can be shown using exact, accurate and reproducible methods.

It has been proposed that generic antibiotics behave differently from the innovator product against pathogenic microorganisms \[[@B4]-[@B6]\]. This is possible if the generic antibiotic does not fulfill quality standards for that pharmaceutical product (purity, content, etc.). For instance, contaminants in generic drugs may interfere with their antibiotic activities.

The MIC and MLC results obtained with different pathogenic strains showed no differences among samples (Tables [10](#T10){ref-type="table"} and [11](#T11){ref-type="table"}). This is probably because the samples were pharmaceutical equivalents. We conclude that generic and novel products perform equally well. In other words, the generic products evaluated in this study fulfill the requirements to be considered for use in antimicrobial therapy.

We also designed an assay to determine critical concentrations using a few selected strains to confirm that all the generic products evaluated were effective in antimicrobial therapy. The results showed no significant differences among samples (Tables [12](#T12){ref-type="table"} and [13](#T13){ref-type="table"}). Moreover, the ratios between the CC of the standard and those of the different samples were similar to their potency levels (Tables [14](#T14){ref-type="table"} and [15](#T15){ref-type="table"}).

Along the same lines, an assay was designed to determine the production of spontaneous mutants in the diffusion gel assay. The results again showed that all the samples behaved similarly, leading us to conclude that none of the samples studied differs markedly in their antimicrobial activities. That is, generic and brand-name products that fulfill the international specifications for manufacturing pharmaceutical products behave similarly to novel products.

Our results are quite different from those of other studies \[[@B4]-[@B6]\]. Some of those studies were conducted using the newest product as a \"standard of comparison\", but the researchers did not take into account that a commercial product may have a range of content between 90% and 120%. Consequently, there will be great variability in the results with respect to the performance of the antibiotic. For instance, if the novel drug product has a hypothetical content of 120% relative to the declared content on the label and the generic product has a hypothetical content of 90%, then the effective content of the generic product would be 75% (90/120) of the novel drug. This could produce misleading results because although both products fulfill the content requirements, the first is at the upper limit and the second at the lower limit. Other assays have compared commercial antibiotic-discs with antibiotic-discs prepared from solutions of commercial products. Again, the exact content of each antibiotic-disc and the exact content of the product are unknown, so the results could be misinterpreted.

It has been proposed that generic antibiotics behave differently from the innovator product against pathogenic microorganisms \[[@B4]-[@B6]\]. This is possible if the generic antibiotic does not fulfill the quality standards for that pharmaceutical product (purity, content, etc.). For instance, contaminants in generic drugs may interfere with their antibiotic activities.

The MIC and MLC results obtained with different pathogenic strains showed no differences among samples (Tables [10](#T10){ref-type="table"} and [11](#T11){ref-type="table"}). This is probably because the samples were pharmaceutical equivalents. We conclude that generic and novel products perform equally well. In other words, the generic products evaluated in this study fulfill the requirements to be considered for use in antimicrobial therapy.

Conclusions
===========

All the samples analyzed by standardized microbiological methods fulfill the requirements for content according to USP XXVII. They all show the same antimicrobial behavior because they have similar MIC, MLC and CC values and produce similar numbers of mutants.
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